Kidney Involvement in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 336-350

  Illei, Gabor G ^a   Balow, James E ^b,c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349152270     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04434-9.50041-5     Document Type: Chapter

References (83)

1. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
2. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
3. Manjunath G, Sarnak MJ, Levey AS Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001, 10:785-792.
4. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004, 31:1557-1559.
5. Sessoms S, Mehta K, Kovarsky J. Quantitation of proteinuria in systemic lupus erythematosus by use of a random, spot urine collection. Arthritis Rheum 1983, 26:918-920.
6. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP The benefit of early treatment with immunosuppressive agents in lupus nephritis [see comments]. J Rheumatol 1994, 21:2046-2051.
7. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004, 65:521-530.
8. Austin HA, Boumpas DT, Vaughan EM, Balow JE Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994, 45:544-550.
9. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003, 111:1416-1421.
10. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
11. Morales JV, Weber R, Wagner MB, Barros EJ Is morning urinary protein/creatinine ratio a reliable estimator of 24-hour proteinuria in patients with glomerulonephritis and different levels of renal function?. J Nephrol 2004, 17:666-672.
12. Hebert LA, Dillon JJ, Middendorf DF, Lewis EJ, Peter JB Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995, 26:432-438.
13. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994, 24:159-171.
14. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans Glomerular Disease Collaborative Network. Kidney Int 1997, 51:1188-1195.
15. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004, 43:28-36.
16. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004, 50:2569-2579.
17. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002, 46:995-1002.
18. Austin HA, Boumpas DT, Vaughan EM, Balow JE High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995, 10:1620-1628.
19. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619.
20. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340:741-745.
21. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343:1156-1162.
22. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980.
23. Donadio JV, Holley KE, Ferguson RH, Ilstrup DM Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978, 299:1151-1155.
24. Donadio JV, Holley KE, Ilstrup DM Cytotoxic drug treatment of lupus nephritis. Am J Kidney Dis 1982, 2(Suppl 1):178-181.
25. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125:549-557.
26. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramón E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131.
27. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM A controlled trial of plasmapheresis therapy in severe lupus nephritis The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992, 326:1373-1379.
28. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994, 3:107-112.
29. Steinberg AD, Decker JL A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974, 17:923-937.
30. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971, 75:165-171.
31. Steinberg AD, Steinberg SC Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only [see comments]. Arthritis Rheum 1991, 34:945-950.
32. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
33. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
34. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993, 119:366-369.
35. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004, 50:3934-3940.
36. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004, 43:197-208.
37. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994, 4:1499-1515.
38. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993, 44:638-642.
39. Radhakrishnan J, Appel AS, Valeri A, Appel GB The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993, 22:135-142.
40. Donadio JV Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 1992, 7(Suppl 1):97-104.
41. Donadio JV, Holley KE, Anderson CF, Taylor WF Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 1974, 6:431-439.
42. Gonzalez-Dettoni H, Tron F. Membranous glomerulopathy in systemic lupus erythematosus. Adv Nephrol Necker Hosp 1985, 14:347-364.
43. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004, 43:269-276.
44. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999, 8:545-551.
45. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998, 31:681-686.
46. Karim MY, Pisoni CN, Ferro L, Tungekar MF, Abbs IC, D'Cruz DP, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005, 44:1317-1321.
47. Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004, 66:2411-2415.
48. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000, 9:241-251.
49. Radhakrishnan J, Kunis CL, D'Agati V, Appel GB Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994, 42:147-154.
50. Austin HA, Vaughan EM, Balow JE Lupus membranous nephropathy: randomized controlled trial of prednisone, cyclosporine and cyclophosphamide. J Am Soc Nephrol 2000, 11(Suppl 9):81A.
51. D'Cruz DP Renal manifestations of the antiphospholipid syndrome. Lupus 2005, 14:45-48.
52. Vaidya S, Wang CC, Gugliuzza C, Fish JC Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998, 12:439-444.
53. Stone JH, Amend WJ, Criswell LA Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999, 34:1040-1047.
54. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990, 15:8-15.
55. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
56. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
57. Bianchi S, Bigazzi R, Campese VM Antagonists of aldosterone and proteinuria in patients with CKD. An uncontrolled pilot study. Am J Kidney Dis 2005, 46:45-51.
58. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
59. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
60. Jacobson SH, Vollenhoven RV, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006, 21:1742-1743.
61. Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 2005, 64:73-77.
62. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545.
63. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
64. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
65. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005, 52:3168-3174.
66. Kaufman J, Wegener WA, Horak ID, Muhammad QU, Ding C, Goldenberg DM, et al. Initial clinical study of immunotherapy in SLE using Epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum 2004, 50:S414.
67. Lorenz HM Abetimus (La Jolla Pharmaceuticals). Curr Opin Investig Drugs 2002, 3:234-239.
68. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003, 48:442-454.
69. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
70. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
71. Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002, 46:1554-1562.
72. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of Tcell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
73. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
74. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
75. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
76. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
77. Aringer M, Graninger WB, Steiner G, Smolen JS Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:3161-3169.
78. Moosig F, Zeuner R, Renk C, Schroder JO IL-1RA in refractory systemic lupus erythematosus. Lupus 2004, 13:605-606.
79. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005, 64:630-633.
80. Tackey E, Lipsky PE, Illei GG Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13:339-343.
81. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006, 295:527-535.
82. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004, 13:168-176.
83. Petri M, Brodsky R, Jones R, Gladstone D, Brodsky I, Johnson L, et al. High-dose cyclophosphamide vs monthly (NIH) cyclophosphamide: one year results. Arthritis Rheum 2004, 50:S406.